Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2018/03/31	2017/12/31	2017/03/31
Balance Sheet			
Current assets			
Cash and cash equivalents	370,282	342,061	210,33
Current financial assets at amortised cost	188,640	0	
Current investments in debt instrument without active market	0	283,586	448,87
Accounts receivable, net	18,716	67,304	17,53
Accounts receivable due from related parties, net	99	1,533	28
Other receivables	3,201	1,262	5,31
Current tax assets	924	2,225	1,97
Current inventories	56,172	46,206	54,68
Prepayments	16.200	11,586	22,18
Other current assets	13,221	9,928	48,58
Total current assets	667,455	765,691	809,77
Non-current assets			
Non-current financial assets at fair value through other comprehensive income	115,790	0	
Non-current financial assets at cost	0	87,000	20,00
Property, plant and equipment	356,178	363,827	351,54
Intangible assets	1,670	1,957	2,10
Deferred tax assets	63,376	56,696	39,02
Other non-current assets	37,095	37,628	86,40
Total non-current assets	574,109	547,108	499,08
Total assets	1,241,564	1,312,799	1,308,85
Current liabilities	1,2+1,00+	1,012,700	1,000,00
Current contract liabilities	6,898	0	
Accounts payable	13,703	9,567	20,73
Other payables	72,538	114,951	29,60
Other payables to related parties	12,000	321	23,00
Other current liabilities	546	2,941	6,54
Total current liabilities	93,685	127,780	56,88
Non-current liabilities	93,003	127,700	50,00
Other non-current liabilities	41,139	41,153	2,25
Total non-current liabilities	41,139	41,153	2,23
Total liabilities	134,824		59,14
Share capital	154,624	100,933	59,14
Ordinary share	1 101 545	1 121 100	1 120 44
Advance receipts for share capital	1,121,545	1,121,180 604	1,120,44 81
	1,121,545		
Total share capital Capital surplus	1,121,545	1,121,784	1,121,25
Capital surplus Capital surplus, additional paid-in capital	000 700	200 404	CO4 07
	266,733	266,494	621,87
Capital surplus, treasury share transactions	2,812	2,812	2,81
Capital surplus, employee share options	34,144	29,856	20,81
Total capital surplus	303,689	299,162	645,49
Retained earnings		(00, (00	
Unappropriated retained earnings (accumulated deficit)	-259,673	-189,469	-429,42
Total retained earnings	-259,673	-189,469	-429,42
Other equity interest			
Total other equity interest	28,790	0	
Treasury shares	-87,611	-87,611	-87,61
Total equity	1,106,740	1,143,866	1,249,71
Total liabilities and equity	1,241,564	1,312,799	1,308,85
Number of share capital awaiting retirement	0	0	
Equivalent issue shares of advance receipts for ordinary share	0	36,500	44,00
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	2,200,00

Provided by: Mycenax Biotech Inc.

## Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2018/01/01To2018/03/31	2017/01/01To2017/03/31
Income Statement		
Total operating revenue	17,447	25,234
Total operating costs	40,746	40,633
Gross profit (loss) from operations	-23,299	-15,399
Gross profit (loss) from operations	-23,299	-15,399
Operating expenses		
Selling expenses	2,355	1,947
Administrative expenses	8,847	11,023
Research and development expenses	34,848	40,106
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	875	0
Total operating expenses	46,925	53,076
Net operating income (loss)	-70,224	-68,475
Non-operating income and expenses		
Total other income	999	6,290
Other gains and losses, net	-7,585	-10,473
Finance costs, net	74	0
Total non-operating income and expenses	-6,660	-4,183
Profit (loss) from continuing operations before tax	-76,884	-72,658
Total tax expense (income)	-6,634	99
Profit (loss) from continuing operations	-70,250	-72,757
Profit (loss)	-70,250	-72,757
Other comprehensive income		
Components of other comprehensive income that will not be reclassified to profit or loss		
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-46	0
Total other comprehensive income	46	0
Total comprehensive income	-70,204	-72,757
Basic earnings per share		
Total basic earnings per share	-0.64	-0.66

Provided by: Mycenax Biotech Inc.

Finacial year: Yearly Unit: NT\$ thousand

2018/01/01To2018/03/31 2017/01/01To2017/03/31 **Accounting Title** Statements of Cash Flows Cash flows from (used in) operating activities, indirect method -72,658 Profit (loss) from continuing operations before tax -76,884 -76,884 -72,658 Profit (loss) before tax Depreciation expense 17,870 13,348 287 234 Amortization expense 875 Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense 39 Interest expense 74 0 Interest income -979 -1,278 Share-based payments 4,288 5,518 Loss (gain) on disposal of property, plan and equipment -112 Impairment loss on non-financial assets 428 179 Total adjustments to reconcile profit (loss) 22,843 17,928 Decrease (increase) in accounts receivable 47,713 5,753 Decrease (increase) in accounts receivable due from related parties 1,434 24,183 Decrease (increase) in other receivable -2,083 -2,389 Decrease (increase) in inventories -10,394 -4,470 Decrease (increase) in prepayments -4,614 -2,196 Decrease (increase) in other current assets 200 -184 Total changes in operating assets 32,256 20,697 Increase (decrease) in contract liabilities 5,015 ſ 4,136 Increase (decrease) in accounts payable -1,332 Increase (decrease) in other payable -43,152 -11,554 Increase (decrease) in other payable to related parties -321 -6 Increase (decrease) in other current liabilities -512 816 Increase (decrease) in net defined benefit liability -14 -15 -34,848 -12,09<sup>-</sup> Total changes in operating liabilities Total changes in operating assets and liabilities -2,592 8,606 Total adjustments 20,25 26,534 Cash inflow (outflow) generated from operations -56,633 -46,124 Income taxes refund (paid) 1,301 -66 Net cash flows from (used in) operating activities -55,332 -46,190 Cash flows from (used in) investing activities -40,000 Acquisition of financial assets at amortised cost C Proceeds from disposal of financial assets at amortised cost 134,946 ſ Acquisition of investments in debt instrument without active market -32,639 0 Proceeds from disposal of investments in debt instrument without active market 0 69,167 Increase in prepayments for investments -67,000 0 Acquisition of property, plant and equipment -606 -10,926 Increase in refundable deposits -80 0 Increase in other financial assets -3,493 -8,337 -13,964 Increase in prepayments for business facilities Interest received 1,123 1,306 Net cash flows from (used in) investing activities 83,553 -54,056 Cash flows from (used in) financing activities Exercise of employee share options 814 0 Net cash flows from (used in) financing activities 0 814 ffect of exchange rate changes on cash and cash equivalents 0 0 Net increase (decrease) in cash and cash equivalents 28,22 -99,432 Cash and cash equivalents at beginning of period 342,061 309,77 Cash and cash equivalents at end of period 370,282 210,339 Cash and cash equivalents reported in the statement of financial position 370,282 210,339 Other items qualifying for cash and cash equivalents under the definition of IAS 7 0 0

## Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

								Unit: NT\$ thousand							
Accounting Title	Ordinary share A	lvance receipts for share capital	Total share capital Ce	apital surplus Unappropriate	iated retained earnings (accumulated deficit) Total re	I retained earnings Unrealised gains (losses) on fina	inancial assets measured at fair value through other con		nancial assets Gains (losses) on effective portion of cash flow	ow hedges Gains (losses) on effective portion of hedges of n	net investments in foreign operations Equity related to non-current a	assets (or disposal groups) classified as held for sale Others Total othe	er equity interest Tr	Treasury shares Tota	al equity
uity at beginning of period	1,121,180	604	1,121,784	299,162	-189,469	-189,469		0	0	0	0	0 0	0	-87,611 1	1,143,866
Effects of retrospective application and retrospective re	live restatement 0	C	0	0	0	0		28,790	0	0	0	0 0	28,790	0	28,790
Equity at beginning of period after adjustments	1,121,180	604	، 1,121,784	299,162	-189,469	-189,469		28,790	0	0	0	0 0	28,790	-87,611 1	1,172,656
Profit (loss)	0	<u>ر</u>	10	0	-70,250	-70,250		0	0	0	0	0 0	0	0	-70,250
Other comprehensive income	0	<u>ر</u>	10	0	46	46		0	0	0	0	0 0	0	0	46
Total comprehensive income	0	C	/0	0	-70,204	-70,204		0	0	0	0	0 0	0	0	-70,204
Share-based payments	365	-604	-239	4,527	0	0		0	0	0	0	0 0	0	0	4,288
Total increase (decrease) in equity	365	-604	-239	4,527	-70.204	-70,204		0	0	0	0	0 0	0	0	-65,916
Equity at end of period	1,121,545		0 1,121,545	303,689	-259,673	-259,673	201	28,790 17/03/31 Statement of Stockholders' Equity Unit: NT\$ thousand	0	0	0	0 0	28,790	-87,611	1,106,740
	1,121,545	0 re capital Capital surplus Unapp	0 1,121,545	303,689	-259,673 cit) Total retained earnings Exchange differences or	-259,673 on translation of foreign financial statements	2017 ealised gains (losses) on financial assets measured at fa	Unit: NT\$ thousand		0 effective portion of cash flow hedges Gains (losses) on effec	0 ctive portion of hedges of net investments in foreign operations Equi	0 0	28,790	-87,611 1,	1,106,740 erest Treas
e Ordinary share Advance receipts		0 re capital Capital surplus Unapp 1,120,812 639,611	0 1,121,545	303,689 ngs (accumulated deficit) -356,669	-259,673 ) Total retained earnings Exchange differences of -356,669	-259,673		Unit: NT\$ thousand		0 effective portion of cash flow hedges Gains (losses) on effect 0	0 ctive portion of hedges of net investments in foreign operations Equi 0	0 0	28,790	-87,611	1,106,740
Title Ordinary share Advance receipts			0 1,121,545	303,689 ings (accumulated deficit) -356,669 -356,669	-259,673 (1) Total retained earnings Exchange differences o -259,673 (1) Total retained earnings (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	-259,673		Unit: NT\$ thousand		0 effective portion of cash flow hedges Gains (losses) on effective 0 0	0 ctive portion of hedges of net investments in foreign operations Equi 0 0	0 0	28,790 d for sale Others To 0 0	-87,611	1,106,740 terest Trea 0 0
Title Ordinary share Advance receipts		1,120,812 639,611	0 1,121,545	303,689 ings (accumulated deficit) -356,669 -356,669 -72,757	-259,673 -259,673 t) Total retained earnings Exchange differences c 9 -356,669 9 -356,669 9 -72,757	-259,673		Unit: NT\$ thousand		0 effective portion of cash flow hedges Gains (losses) on effect 0 0 0	0 ctive portion of hedges of net investments in foreign operations Equi 0 0 0	0 0	28,790 d for sale Others To 0 0 0 0	-87,611	1,106,740 terest Trea 0 0 0
Title Ordinary share Advance receipts		1,120,812 639,611	0 1,121,545	303,689 ings (accumulated deficit) -356,669 -356,669 -72,757 0	-259,673 (t) Total retained earnings Exchange differences c 9 -356,669 9 -356,669 7 -72,757 0 0	-259,673		Unit: NT\$ thousand		0 effective portion of cash flow hedges Gains (losses) on effect 0 0 0 0	0 ctive portion of hedges of net investments in foreign operations Equi 0 0 0 0	0 0	28,790 d for sale Others To 0 0 0 0 0 0 0 0	-87,611	1,106,740 terest Trea 0 0 0 0
Title     Ordinary share     Advance receipts       d     1,120,005       d after adjustments     1,120,005       0     0		1,120,812 639,611	0 1,121,545	303,689 303,689 303,689 -356,669 -356,669 -72,757 0 -72,757	-259,673 it) Total retained earnings Exchange differences c 9 -356,669 7 -72,757 0 0 -72,757	-259,673 Dn translation of foreign financial statements Unrea 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Unit: NT\$ thousand		0 effective portion of cash flow hedges Gains (losses) on effect 0 0 0 0 0	0 ctive portion of hedges of net investments in foreign operations Equi 0 0 0 0 0 0	0 0	28,790 d for sale Others To 0 0 0 0 0 0 0 0 0 0 0 0 0 0	-87,611	1,106,740 terest Tre: 0 0 0 0 0
Title     Ordinary share     Advance receipts       d     1,120,005       d after adjustments     1,120,005       0     0       ne     0		1,120,812 639,611	0 1,121,545	303,689 nings (accumulated deficit -356,669 -72,757 0 -72,757 0	-259,673 it) Total retained earnings Exchange differences ( 39 -356,669 7 -72,757 0 0 7 -72,757 0 0 7 -72,757 0 0	-259,673 on translation of foreign financial statements Unree 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Unit: NT\$ thousand		o effective portion of cash flow hedges Gains (losses) on effect 0 0 0 0 0 0 0 0 0 0 0 0 0	0 ctive portion of hedges of net investments in foreign operations Equi 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0	28,790 d for sale Others To 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	-87,611	1,106,740 terest Tre 0 0 0 0 0 0
Title     Ordinary share     Advance receipts       d     1,120,005       d after adjustments     1,120,005       0     0       ne     0		1,120,812 639,611	0 1,121,545	303,689 nings (accumulated deficit -356,665 -72,757 0 -72,757	-259,673 it) Total retained earnings Exchange differences ( 39 -356,669 39 -356,669 7 -72,757 0 0 7 -72,757 0 0 7 -72,757 0 -0 7 -72,757	-259,673 on translation of foreign financial statements Unrex 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Unit: NT\$ thousand		o effective portion of cash flow hedges Gains (losses) on effect 0 0 0 0 0 0 0 0 0 0 0 0 0	0 ctive portion of hedges of net investments in foreign operations Equi 0 0 0 0 0 0	0 0	28,790 d for sale Others To 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	-87,611	1,106,740 terest Tre 0 0 0 0 0 0 0

Accounting Title	Ordinary share Advance receipts for s	hare capital Total share cap	apital Capital surplus Unappropriated retain	ained earnings (accumulated deficit) Iotal re	retained earnings Unrealised gains	ins (losses) on financial assets measured at fair value through other comprehensive income Unrealized gains (losses) on a	n available-for-sale financial assets Gains (losses) on effective portion of	f cash flow hedges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-current assets (or disposal group	ups) classified as held for sale Others Total other equity inter	terest Treasury shares	s Total equity
Equity at beginning of period	1,121,180	604 1,12	1,784 299,162	-189,469	-189,469	0	0	0 0	0 0	0 -87,611	1 1,143,866
Equity at beginning of period Effects of retrospective application and retrospective restatement	.it 0	0	0 0	0	0	28,790	0	0 0	0 0 28,7	28,790 0	0 28,790
Equity at beginning of period after adjustments	1,121,180	604 1,12	. 1,784 299,162	-189,469	-189,469	28,790	0	0 0	0 0 28,7	28,790 -87,611	1 1,172,656
Profit (loss)	0	0	0 0	-70,250	-70,250	0	0	0 0	0 0	0 0	0 -70,250
Other comprehensive income	0	0	00	46	46	0	0	0 0	0 0	0 0	0 46
Total comprehensive income	0	0	0 0	-70,204	-70,204	0	0	0 0	0 0	0 0	0 -70,204
Share-based payments	365	-604	-239 4,527	0	0	0	0	0 0	0 0	0 0	0 4,288
Total increase (decrease) in equity	365	-604	-239 4,527	-70,204	-70,204	0	0	0 0	0 0	0 0	0 -65,916
	1 121 545	0 1 12	_1.545 303.689	-259,673	-259,673	28,790	0	0 0	0 0 28,	28,790 -87,611	1 1,106,740
Equity at end of period						2017/03/31 Statement of Stockhold Unit: NT\$ thousand					
Title Ordinary share Advance receipts for sha	nare capital Total share capital Capital sur	us Unappropriated retain	əd earnings (accumulated deficit) Total r	I retained earnings Exchange differences on	n translation of foreign financial st	2017/03/31 Statement of Stockhold Unit: NT\$ thousand statements Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income Unre		ses) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-curren	ent assets (or disposal groups) classified as held for sale Othe	thers Total other equit	ty interest Tr
Title Ordinary share Advance receipts for sha	re capital Total share capital Capital su 807 1,120,812 633	<sup>1</sup> us Unappropriated retair	ed earnings (accumulated deficit) Total	retained earnings Exchange differences on	ו translation of foreign financial st	Unit: NT\$ thousand		ses) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-curren	ent assets (or disposal groups) classified as held for sale Othe 0	thers Total other equit	ty interest Ti
Title Ordinary share Advance receipts for sha	re capital Total share capital Capital su 807 1,120,812 63 807 1,120,812 63	lus Unappropriated retain	red earnings (accumulated deficit) Total -356,669 -356,669	retained earnings Exchange differences on -356,669 -356,669	ו translation of foreign financial st	Unit: NT\$ thousand		ses) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-curren 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ent assets (or disposal groups) classified as held for sale Othe 0 0	thers Total other equit	ty interest Tr
Title     Ordinary share     Advance receipts for share       od     1,120,005       od after adjustments     1,120,005       0     0	re capital Total share capital Capital st 807 1,120,812 65 807 1,120,812 63 0 0	Unappropriated retai	ned earnings (accumulated deficit) Total -356,669 -356,669 -72,757	retained earnings Exchange differences on -356,669 -356,669 -72,757	ו translation of foreign financial s	Unit: NT\$ thousand		ses) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-curren 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ent assets (or disposal groups) classified as held for sale Othe 0 0 0	thers Total other equit	ty interest Ti 0 0
Title     Ordinary share     Advance receipts for share       od     1,120,005       od after adjustments     1,120,005       0     0	re capital Total share capital Capital su 807 1,120,812 63 0 0 0	blus Unappropriated retai	ned earnings (accumulated deficit) Total -356,669 -356,669 -72,757 0	retained earnings Exchange differences or -356,669 -356,669 -72,757 0	n translation of foreign financial s	Unit: NT\$ thousand		ses) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-curren 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ent assets (or disposal groups) classified as held for sale Otho 0 0 0 0	thers Total other equit	ty interest T 0 0 0
Title     Ordinary share     Advance receipts for share       od     1,120,005       od after adjustments     1,120,005       0     0	re capital Total share capital Capital su 807 1,120,812 6: 807 1,120,812 6: 0 0 0 0 0 0	blus         Unappropriated reta:           611         611           611         611           0         0           0         0	ned earnings (accumulated deficit) Total -356,669 -356,669 -72,757 0 -72,757	l retained earnings Exchange differences or -356,669 -356,669 -72,757 0 -72,757	n translation of foreign financial s	Unit: NT\$ thousand		ses) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-curren 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ent assets (or disposal groups) classified as held for sale Othe 0 0 0 0	thers Total other equit 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ty interest T 0 0 0 0 0
Title     Ordinary share     Advance receipts for share       od     1,120,005       od after adjustments     1,120,005       0     0       me     0       ne     0       440	are capital Total share capital Capital su 807 1,120,812 6 807 1,120,812 6 0 0 0 0 0 0 0 0 7 447 5	blus         Unappropriated reta           611         611           0         0           0         0           85         5	ned earnings (accumulated deficit) Total -356,669 -356,669 -72,757 0 -72,757 0	I retained earnings Exchange differences or -356,669 -356,669 -72,757 0 -72,757 0	n translation of foreign financial s	Unit: NT\$ thousand		ses) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-curren 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ent assets (or disposal groups) classified as held for sale Othe 0 0 0 0 0 0 0	thers Total other equit 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ty interest 1 0 0 0 0 0 0
Title     Ordinary share     Advance receipts for share       od     1,120,005       od after adjustments     1,120,005       0     0	are capital Total share capital Capital s.       807     1,120,812       6     6       807     1,120,812       0     0       0     0       0     0       7     447	olus         Unappropriated reta           611         611           0         0           0         0           85         85	ned earnings (accumulated deficit) Total -356,669 -72,757 0 -72,757 0 -72,757 0 -72,757	l retained earnings Exchange differences or -356,669 -356,669 -72,757 0 -72,757 0 -72,757 0 -72,757	n translation of foreign financial s	Unit: NT\$ thousand		ses) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-curren 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ent assets (or disposal groups) classified as held for sale Othe 0 0 0 0 0 0 0 0 0	thers Total other equit 0 0 0 0 0 0 0 0	ty interest 0 0 0 0 0 0 0 0

## 2018/03/31 Statement of Stockholders' Equity